title: Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age.
abstract: Previous studies of oral contraceptives and breast cancer indicate that recent use slightly increases risk, but most studies relied on self-reported use and did not examine contemporary oral contraceptive formulations. This nested case-control study was among female enrollees in a large U.S. integrated health care delivery system. Cases were 1,102 women ages 20 to 49 years diagnosed with invasive breast cancer from 1990 to 2009. Controls were randomly sampled from enrollment records (n = 21,952) and matched to cases on age, year, enrollment length, and medical chart availability. Detailed oral contraceptive use information was ascertained from electronic pharmacy records and analyzed using conditional logistic regression, ORs, and 95% confidence intervals (CI). Recent oral contraceptive use (within the prior year) was associated with an increased breast cancer risk (OR, 1.5; 95% CI, 1.3-1.9) relative to never or former OC use. The association was stronger for estrogen receptor-positive (ER(+); OR, 1.7; 95% CI, 1.3-2.1) than estrogen receptor-negative (ER(-)) disease (OR, 1.2, 95% CI, 0.8-1.8), although not statistically significantly different (P = 0.15). Recent use of oral contraceptives involving high-dose estrogen (OR, 2.7; 95% CI, 1.1-6.2), ethynodiol diacetate (OR, 2.6; 95% CI, 1.4-4.7), or triphasic dosing with an average of 0.75 mg of norethindrone (OR, 3.1; 95% CI, 1.9-5.1; Pheterogeneity compared with using other oral contraceptives = 0.004) was associated with particularly elevated risks, whereas other types, including low-dose estrogen oral contraceptives, were not (OR, 1.0; 95% CI, 0.6-1.7). Our results suggest that recent use of contemporary oral contraceptives is associated with an increased breast cancer risk, which may vary by formulation. If confirmed, consideration of the breast cancer risk associated with different oral contraceptive types could impact discussions weighing recognized health benefits and potential risks.
authors.affiliation: Group Health Research Institute, Group Health Cooperative, Seattle, Washington. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Epidemiology, University of Washington, Seattle, Washington. ebeaber@fhcrc.org.
authors.forename: Elisabeth F
authors.initials: EF
authors.lastname: Beaber
authors.affiliation: Group Health Research Institute, Group Health Cooperative, Seattle, Washington. Department of Epidemiology, University of Washington, Seattle, Washington.
authors.forename: Diana S M
authors.initials: DS
authors.lastname: Buist
authors.affiliation: Department of Biostatistics, University of Washington, Seattle, Washington.
authors.forename: William E
authors.initials: WE
authors.lastname: Barlow
authors.affiliation: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Epidemiology, University of Washington, Seattle, Washington.
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: Malone
authors.affiliation: Group Health Research Institute, Group Health Cooperative, Seattle, Washington. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Epidemiology, University of Washington, Seattle, Washington. Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington.
authors.forename: Susan D
authors.initials: SD
authors.lastname: Reed
authors.affiliation: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Epidemiology, University of Washington, Seattle, Washington.
authors.forename: Christopher I
authors.initials: CI
authors.lastname: Li
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000139:chemically induced / Q000453:epidemiology*; D016022:Case-Control Studies; D003276:Contraceptives, Oral / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry*; D005260:Female; D006801:Humans; D008875:Middle Aged; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D055815:Young Adult
chemical_list: D003276:Contraceptives, Oral
references.citation: Contraception. 2012 Apr;85(4):342-50
references.pmid: 22067757
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2496-502
references.pmid: 20802021
references.citation: Int J Epidemiol. 1998 Dec;27(6):1033-7
references.pmid: 10024199
references.citation: J Natl Cancer Inst. 1994 Apr 6;86(7):505-14
references.pmid: 8133534
references.citation: Eur J Contracept Reprod Health Care. 2004 Sep;9(3):182-93
references.pmid: 15697108
references.citation: Natl Health Stat Report. 2012 Oct 18;(60):1-25
references.pmid: 24988814
references.citation: Am J Epidemiol. 1993 Nov 1;138(9):697-703
references.pmid: 8237985
references.citation: Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):96-8
references.pmid: 16427730
references.citation: Am J Epidemiol. 2009 Feb 15;169(4):473-9
references.pmid: 19074777
references.citation: Maturitas. 2003 Dec 10;46 Suppl 1:S7-S16
references.pmid: 14670641
references.citation: Breast Cancer Res Treat. 1998 Jul;50(2):175-84
references.pmid: 9822222
references.citation: Breast Cancer Res Treat. 2001 Jan;65(2):163-9
references.pmid: 11261832
references.citation: Rev Endocr Metab Disord. 2002 Sep;3(3):211-24
references.pmid: 12215716
references.citation: Contraception. 1996 Sep;54(3 Suppl):1S-106S
references.pmid: 8899264
references.citation: N Engl J Med. 2002 Jun 27;346(26):2025-32
references.pmid: 12087137
references.citation: Br J Cancer. 2003 Jan 13;88(1):50-7
references.pmid: 12556959
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):2073-9
references.pmid: 20647407
references.citation: Contraception. 1986 Feb;33(2):127-37
references.pmid: 3698594
references.citation: Cancer Causes Control. 2003 Mar;14(2):151-60
references.pmid: 12749720
references.citation: Am J Epidemiol. 2000 Apr 1;151(7):703-14
references.pmid: 10752798
references.citation: Int J Cancer. 1991 May 10;48(2):206-10
references.pmid: 2019467
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1375-81
references.pmid: 12433714
references.citation: Lancet. 1996 Jun 22;347(9017):1713-27
references.pmid: 8656904
references.citation: Contraception. 1997 Dec;56(6):373-8
references.pmid: 9494771
references.citation: Pharmacoepidemiol Drug Saf. 1996 May;5(3):141-7
references.pmid: 15073830
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1157-66
references.pmid: 19336554
references.citation: Contraception. 2008 Apr;77(4):264-9
references.pmid: 18342649
references.citation: Int J Cancer. 2007 Dec 1;121(11):2517-23
references.pmid: 17657739
references.citation: Am J Public Health. 1991 Jan;81(1):90-6
references.pmid: 1983923
references.citation: Cancer Res. 2010 Jan 15;70(2):575-87
references.pmid: 20068186
references.citation: Breast J. 2008 Sep-Oct;14(5):450-5
references.pmid: 18657146